PURPOSE: In order to obtain better insight into the genetic background of nodular melanoma (NM), we aimed to analyse the frequency of CDKN2A and C-MYC copy number changes. The impact of these aberrations on the metastatic potential and patient's survival was considered. METHODS: Fluorescent in situ hybridization was used to analyse the C-MYC and CDKN2A genes on isolated nuclei from 49 paraffin-embedded primary NMs. RESULTS: Thirty-six (73.47%) melanoma samples showed CDKN2A deletion while 11 of these 36 (22.45%) additionally displayed C-MYC increased copy numbers. Cases positive for metastases more commonly displayed CDKN2A deletions. However, the combined C-MYC and CDKN2A aberrations were found predominantly in the non-metastasizing group of primary NM. The survival analysis furthermore demonstrated that patients with combined CDKN2A and C-MYC aberrations have a significantly better prognosis than carriers of CDKN2A deletion only. CONCLUSIONS: We conclude that the C-MYC increased copy number changes on the background of CDKN2A deletions seem to be related to a low metastatic potential and better patients' outcome in primary NMs.
PURPOSE: In order to obtain better insight into the genetic background of nodular melanoma (NM), we aimed to analyse the frequency of CDKN2A and C-MYC copy number changes. The impact of these aberrations on the metastatic potential and patient's survival was considered. METHODS: Fluorescent in situ hybridization was used to analyse the C-MYC and CDKN2A genes on isolated nuclei from 49 paraffin-embedded primary NMs. RESULTS: Thirty-six (73.47%) melanoma samples showed CDKN2A deletion while 11 of these 36 (22.45%) additionally displayed C-MYC increased copy numbers. Cases positive for metastases more commonly displayed CDKN2A deletions. However, the combined C-MYC and CDKN2A aberrations were found predominantly in the non-metastasizing group of primary NM. The survival analysis furthermore demonstrated that patients with combined CDKN2A and C-MYC aberrations have a significantly better prognosis than carriers of CDKN2A deletion only. CONCLUSIONS: We conclude that the C-MYC increased copy number changes on the background of CDKN2A deletions seem to be related to a low metastatic potential and better patients' outcome in primary NMs.
Authors: C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito Journal: J Clin Oncol Date: 2001-08-15 Impact factor: 44.544
Authors: Kolja Freier; Stefan Joos; Christa Flechtenmacher; Frauke Devens; Axel Benner; Franz X Bosch; Peter Lichter; Christof Hofele Journal: Cancer Res Date: 2003-03-15 Impact factor: 12.701
Authors: Soledad R Alonso; Pablo Ortiz; Marina Pollán; Beatriz Pérez-Gómez; Lydia Sánchez; Ma Jesús Acuña; Raquel Pajares; Francisco J Martínez-Tello; Carlos M Hortelano; Miguel A Piris; José L Rodríguez-Peralto Journal: Am J Pathol Date: 2004-01 Impact factor: 4.307
Authors: Göran Mattsson; Soo Yong Tan; David J P Ferguson; Wendy Erber; Susan H Turner; Teresa Marafioti; David Y Mason Journal: J Mol Diagn Date: 2007-08-09 Impact factor: 5.568
Authors: Caroline Conway; Samantha Beswick; Faye Elliott; Yu-Mei Chang; Juliette Randerson-Moor; Mark Harland; Paul Affleck; Jerry Marsden; D Scott Sanders; Andy Boon; Margaret A Knowles; D Timothy Bishop; Julia A Newton-Bishop Journal: Genes Chromosomes Cancer Date: 2010-05 Impact factor: 5.006